

1 **Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Hydroxychloroquine in Healthy**
2 **Volunteers**

3 Y.A. de Reus¹, P. Hagedoorn², M.G.G. Sturkenboom³, F.Grasmeijer^{2,4}, M.S. Bolhuis³, I. Sibum², H.A.M.
4 Kerstjens¹, H.W. Frijlink², O.W. Akkerman^{1,5*}

5 ¹ University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases
6 and Tuberculosis, Groningen, the Netherlands

7 ² University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen,
8 the Netherlands

9 ³ University of Groningen, University Medical Center Groningen, Groningen, Department of Clinical
10 Pharmacy and Pharmacology, the Netherlands

11 ⁴ PureIMS B.V., Roden, the Netherlands

12 ⁵ University of Groningen, University Medical Center Groningen, TB center Beatrixoord, Groningen,
13 the Netherlands

14

15 *Corresponding author

Onno W. Akkerman, MD, PhD

University Medical Center Groningen

PO Box 30001, 9700 RB Groningen, the Netherlands

e-mail: o.w.akkerman@umcg.nl

phone: +31 50 3610857

16

17 **Word count abstract:** 200

18 **Word count full text:** 3052

19 **Keywords:** SARS-CoV-2, covid-19, hydroxychloroquine, inhalation

20

21 **ABSTRACT**

22

23 **Rationale:**

24 Inhaled antimicrobials enable high local concentrations where needed and, compared to orally
25 administration, greatly reduce the potential for systemic side effects. In SARS-CoV-2 infections,
26 hydroxychloroquine (HCQ) administered as dry powder via inhalation could be safer than oral HCQ
27 allowing for higher and therefore more effective pulmonary concentrations without dose limiting
28 toxic effects.

29

30 **Objectives:** To assess the local tolerability, safety and pharmacokinetic parameters of HCQ
31 inhalations in single ascending doses of 5, 10 and 20 mg using the Cyclops dry powder inhaler.

32

33 **Methods:** 12 healthy volunteers were trained in inhaling HCQ correctly. Local tolerability and safety
34 were assessed by pulmonary function tests, ECG and recording adverse events. To estimate systemic
35 exposure, serum samples were collected before and 0.5, 2 and 3.5 h after inhalation.

36

37 **Results and discussion:** Dry powder HCQ inhalations were well tolerated by the participants, except
38 for transient bitter taste in all participants and minor coughing irritation. There was no significant
39 change in QTc-interval or drop in FEV₁ post inhalation. The serum HCQ concentration remained
40 below 10 µg/L in all samples.

41

42 **Conclusion:** Inhaled dry powder HCQ is safe and well tolerated. Our data support further studies with
43 inhaled HCQ dry powder to evaluate pulmonary pharmacokinetics and efficacy is warranted.

44

45 1. INTRODUCTION

46 In late December 2019 an outbreak of the novel coronavirus, Severe Acute Respiratory Syndrome
47 Coronavirus 2 (SARS-CoV-2), started in Wuhan, China, and caused the spread of corona virus disease
48 2019 (COVID-19) [1]. The WHO declared the epidemic of COVID-19 a pandemic on March 12th, 2020
49 [2]. The virus is still rapidly spreading with over 41 million cases and 1.1 million deaths reported
50 worldwide in the second week of November 2020 [3]. Currently Europe is again facing a steep rise in
51 incidence and is in its 'second wave' now autumn has come.

52

53 Given that this pandemic has a huge impact on healthcare systems, social life and economics, there is
54 an urgent need for treatment of COVID-19. Currently available treatment options are mostly used in
55 hospitalized patient: the anti-inflammatory drug dexamethasone and anti-viral nucleoside analog
56 prodrug remdesivir. These drugs reduce mortality and shorten time to recovery respectively [4, 5]. In
57 addition to an effective treatment there is also the need to be able to prevent and decrease
58 transmission in the general population and moreover in healthcare workers or other high-risk
59 groups. We are awaiting results from clinical trials with vaccines; as these will almost certainly not be
60 100% effective, alternatives should be investigated for both treatment in early disease and
61 prevention of transmission. Repositioning old drugs for use as antiviral or anti-inflammatory
62 treatment is an interesting strategy because the safety profile, side effects, posology and drug
63 interactions are already known which can speed up the trial program duration considerably.

64 Among those drugs is hydroxychloroquine sulphate (HCQ), which is mostly used in rheumatologic
65 conditions because of its immune-modulatory effects [6, 7]. HCQ has proven to be effective in *in vitro*
66 Vero cell systems infected with SARS-CoV-2 in two separate Chinese studies [8, 9]. Angiotensin
67 converting enzyme 2 (ACE2) receptor expressing cells play an important role in the pathogenesis of
68 SARS-CoV-2 infection, as the virus uses this receptor for entering the cell [8, 10-12]. HCQ impairs the
69 terminal glycosylation of ACE2 and thereby inhibits cell-binding and consequently entry of the virus
70 into the cell [13-15]. Furthermore, HCQ also blocks transport of SARS-CoV-2 from early endosomes to

71 endolysosomes, a requirement to release the viral genome [8, 9, 16]. Finally, HCQ has anti-
72 inflammatory properties as it influences the generation of pro-inflammatory cytokines and
73 endosomal inhibition of toll-like receptors, which have a major role in innate immune response [8,
74 17-20]. Based on these in vitro findings oral HCQ was used abundantly worldwide in the beginning of
75 the COVID-19 pandemic, both off label and in clinical trials. Some observational studies showed
76 clinical benefit and antiviral effects [21-25] while others did not [26, 27] or were inconclusive [28,
77 29]. Currently both the FDA and EMA advice against the off-label use of oral HCQ based on the large
78 clinical RECOVERY trial that showed no beneficial effects on 28-day mortality [30]. The prospective
79 European DISCOVERY trial and WHO SOLIDARITY trial have discontinued the oral HCQ treatment
80 because of a lack of effect on mortality arms as well. The failing treatment with oral HCQ may be
81 explained by insufficient concentrations in alveolar epithelial cells due to its enormous volume of
82 distribution of 5500 L [31]. Raising the oral dose is not an option since this is limited by adverse or
83 even toxic effects, including the risk of cardiovascular toxicity (QTc prolongation).

84 Pulmonary administration of HCQ can be the solution to reach high local pulmonary concentrations
85 without systemic toxicity [32, 33]. For this purpose, we developed a dry powder formulation of HCQ
86 suitable for inhalation using the Cyclops dry powder inhaler. The Cyclops is a high dose disposable
87 inhaler that enables effective dispersion of up to 50 mg of drug in the preferred size range for
88 inhalation [34]. The aim of this study was to assess local tolerability and safety of increasing doses of
89 dry powder HCQ administered using the Cyclops to healthy volunteers. The chosen doses of 5 mg, 10
90 mg and 20 mg are comparable with known doses of inhaled nebulized HCQ and thus expected to be
91 safe [33, 35-38]

92

93

94

95

96 **2. METHODS**

97 *Study design*

98 This study was an open-label phase 1a single ascending dose study with twelve healthy volunteers. It
99 was performed at the University Medical Center Groningen (UMCG) location Beatrixoord (Groningen,
100 the Netherlands) between in September and October 2020. It included administration of HCQ dry
101 powder per inhalation using the Cyclops in single ascending doses of 5 mg, 10 mg, and 20 mg. In- and
102 exclusion criteria are listed in Table 1. The study was approved by the local medical ethical review
103 committee (METc UMCG, Groningen, The Netherlands, METc number 2020.168). The study was
104 performed according to the Helsinki declaration (Fortaleza, Brazil, 2013) and was registered at
105 clinicaltrials.gov (NCT04497519). The study was conducted with the written informed consent of all
106 participating subjects.

107 *Study drug*

108 The dry powder formulation of HCQ was developed at the department of Pharmaceutical Technology
109 and Biopharmacy of the University of Groningen. For the production of the study drug
110 hydroxychloroquine sulphate was obtained from Ofipharma BV (Ter Apel, the Netherlands). The HCQ
111 Cyclops was produced by PureIMS B.V. (Roden, the Netherlands). Each Cyclops contained a nominal
112 dose of 5 mg or 10 mg HCQ; the 20 mg dose was administered as 2 successive inhalations with 10 mg
113 of HCQ.

114 *Objectives and procedures*

115 The primary objective was to assess local tolerability and safety. Local tolerability was assessed by
116 spirometry combined with active questioning about adverse events experienced by the participants.
117 A drop of the forced expiratory volume in the first second (FEV₁) of 15% or more after inhalation of
118 HCQ compared to baseline FEV₁ was considered clinically significant and critical to decide on
119 proceeding with the next ascending dose. Spirometry was performed before inhalation (baseline)

120 and 35 minutes and 95 minutes after inhalation of HCQ according to the ATS/ERS guidelines [39].
121 Adverse events were continually assessed during the study day. Cough for more than one hour or
122 any other reported adverse event that made either the physician or the participant decide to stop
123 participation was considered critical to decide on proceeding with the next ascending dose. ECGs
124 were performed to assess the QTc interval as safety parameter. An ECG was obtained at the
125 screening visit, before inhalation of the first dose and approximately 3.5 hours after each HCQ
126 inhalation. An observed QTc interval of more than 500 ms was also considered critical on proceeding
127 with the next ascending dose. All tolerability and safety endpoints were discussed with a Data Safety
128 Monitoring Board (DSMB) after all twelve participants completed a dose step before proceeding to
129 the next ascending dose.

130 The secondary objectives were to assess systemic exposure of HCQ and measurement of inspiratory
131 flow parameters. To determine the systemic exposure, blood samples were collected from an
132 intravenous indwelling cannula just before inhalation and 30 minutes, 2 hours and 3.5 hours after
133 inhalation of HCQ. These samples were analyzed using a validated liquid chromatography tandem
134 mass spectrometry (LC-MS/MS) method performed at the laboratory of the department of Clinical
135 Pharmacy and Pharmacology of the UMC Groningen (ISO15189:2012 (M170) certified). The limit of
136 quantification is 10 µg/L. The delivered dose was determined by subtracting the powder residue
137 inside the Cyclops after inhalation from the exact weighed dose pre inhalation. The powder residues
138 in the Cyclops were dissolved in demineralized water and the solutions were analyzed with a Thermo
139 Scientific spectrophotometer (Genesys 150 UV-VIS, The Netherlands) at a wavelength of 236.0 nm.

140 Prior to inhalation of the study drug, study participants received inhalation instructions followed by
141 training regarding handling of the device and performing a correct inhalation maneuver. Training
142 was done using an empty Cyclops connected to a laptop, with in-house developed software
143 application (labVIEW, National Instruments, the Netherlands) for recording of and processing of flow
144 curves generated through the device. When a series of consistent flow curves meeting the criteria for

145 good inhaler performance was obtained during training, a similarly instrumented Cyclops with HCQ
146 was handed to the participant. Inspiratory flow parameters were recorded during each drug
147 administration.

148 *Data management and statistics*

149 Study data were collected and managed using Research Electronic Data Capture (REDCap) [40,
150 41]. Statistical analysis was performed with SPSS version 23. Data from all eligible subjects who
151 received at least one dose of the study drug were included in analyses of safety. Data were
152 summarized using descriptive statistics. At each visit and timepoint, testing for differences in pre- to
153 post-dose changes in FEV1 (liters) and QTc interval were performed using the paired T-test or
154 Wilcoxon rank sum test. P values below 0.05 were considered statistically significant.

155

156 **RESULTS**

157 Twelve healthy volunteers were enrolled, and all completed the study. See table 2 for all patient
158 characteristics. All participants had normal baseline QTc interval and G6PD-deficiency was excluded
159 in all participants. At the screenings visit pregnancy was excluded in female participants.

160 There were no serious adverse events observed during or after the study (see table 3). None of the
161 participants had cough longer than the pre-defined safety period of one hour. Minor complaints of
162 cough were reported four times, each in a different participant, directly after inhalation of HCQ; two
163 times after a dose of 10 mg HCQ and two times after a dose of 20 mg HCQ. Complaints varied from
164 experience of an itchy or tickling sensation in the throat to a single or a few observed coughs that
165 were self-limiting. Two participants reported minimal dyspnea which disappeared after coughing or
166 spontaneously within 4 minutes after inhalation. All participants mentioned bitter taste after
167 inhalation. In most participants this lasted for 5-10 minutes, but one participant reported the bitter
168 taste for 2 hours. Participants were advised to rinse their mouth with water or eat something after
169 the dose was administered with satisfying effect. Two participants had complaints of slight nausea
170 relating to the bitter taste; one for 5 minutes after a dose of 5 mg HCQ and one for 70 minutes after
171 a dose of 10 mg HCQ. Sore throat was reported by three participants. Two participants developed
172 symptoms of upper respiratory tract infection in the following days of which one tested positive by
173 PCR nasopharyngeal swab for SARS-CoV-2 two days after the last study visit. One participant
174 experienced some hoarseness, which disappeared after drinking some water. Two other adverse
175 events were recorded. One participant with an intrauterine contraceptive device in situ experienced
176 minor spotting two days after inhalation of HCQ after both the 5 mg and 10 mg dose. This is not
177 mentioned as a known side-effect of oral HCQ [42]. One participant mentioned dry eyes once at a
178 dose of 20 mg, which seemed to be related to the dry hospital environment and not to
179 administration of the study drug.

180 None of the participants showed a significant drop in FEV₁ ($\geq 15\%$) at any time point after HCQ
181 administration (see table 4). A maximum drop of -7.51% was observed 95 minutes after inhalation of
182 5 mg HCQ. This participant mentioned a sort of burning sensation at the chest at that moment as
183 well but no dyspnea, something he also recognizes while running.

184 None of the participants had a QTc prolongation ≥ 500 , nor even ≥ 450 ms. Mean QTc interval was
185 412 ± 21 ms (range 384-441) at baseline. This did not change significantly 3.5 hour after inhalation of
186 5 mg, 10 mg and 20 mg HCQ, respectively (see table 5).

187 In all participants, the serum HCQ concentrations sampled 30 minutes, 2 hours and 3.5 hours, were
188 below the detection level of 10 $\mu\text{g/L}$ irrespective of dose. The mean delivered dose was 3.16 mg
189 (63%) after administration of 5 mg HCQ, 6.95 mg (70%) after administration of 10 mg HCQ and 14.86
190 mg (75%) after administration of 20 mg HCQ. Based on the recorded inspiratory flow parameters, all
191 participants correctly performed the inhalation maneuvers.

192

193

194 **DISCUSSION**

195 Pulmonary administration of HCQ for early COVID-19 treatment or prevention in post-exposed
196 individuals might be better than oral administration of HCQ due to the pharmacological properties of
197 HCQ. Hypothetically, it can reach higher pulmonary concentrations compared to oral HCQ while
198 using much lower doses and exerting lower systemic exposure. This phase 1 study with inhaled HCQ
199 with three different doses showed good local tolerability and safety without significant systemic side
200 effects.

201

202 Coughing was reported four times out of a total of 36 administered doses (11%) in four different
203 participants and was very mild in severity. Coughing is often reported after inhalation of
204 antimicrobials by both wet nebulization and dry powder inhalation, with data mainly available from
205 cystic fibrosis patients treated with colistin or tobramycin. In general, this population cough is more
206 frequently reported after dry powder inhalation (ranging from 75% - 90%) than after nebulization
207 (ranging from 31% - 78%) in these patients, although some studies found no differences [43-45]. The
208 trigger for both cough and probably bitter taste is deposition of the drug in the oropharynx. This
209 could be expected since HCQ is a quinoline known for its extremely bitter taste (249 on a bitter scale
210 compared to caffeine at 46) [46]. However, the majority reported that the taste was not disturbing
211 since the participants were warned beforehand, it was minor, and it disappeared within a few
212 minutes after HCQ inhalation or even faster when rinsing the mouth with water or eating something
213 directly after inhalation.

214

215 Bronchus obstruction was not a problem after inhalation of HCQ dry powder; in none of the twelve
216 participants experienced a drop in FEV₁ of more than 15%. The maximum drop was 7.5 % compared
217 to baseline and this was not accompanied by dyspnea. One participant did mention a light burning
218 sensation at the chest at that moment, something he also experienced while running. Although not
219 formerly diagnosed, this participant might suffer from a mild exercise induced asthma. Nevertheless,

220 we believe that HCQ dry powder can be used safely in asthma patients as well, since aerosolized HCQ
221 has been applied in a phase I clinical study to assess safety for use in asthma and was concluded to
222 be safe and well tolerated in 31 healthy individuals in doses up to 20 mg daily for 7 days [33, 36]. In
223 2006, a phase 2 clinical trial with aerosolized HCQ as anti-inflammatory treatment for patients with
224 asthma followed. A dose of 20 mg daily was tolerated for up to 21 days, but it failed to meet the
225 primary clinical endpoints for effective asthma treatment; relative improvement in FEV₁ compared to
226 baseline was not statistically significant after treatment compared to placebo [33, 37]. None of these
227 participants had significant ECG changes and side effects consisted of headache and nausea only [33,
228 36, 37].

229

230 HCQ serum concentrations were below the quantification limit of 10 µg/L in all participants and
231 irrespective of dose or timepoints. Possibly our timing of blood sampling was sub optimal. The
232 timepoints were chosen based on the absorption rate after oral administration, because data after
233 inhalation were not available at that time. If the maximum concentration (C_{max}) occurs very shortly
234 after inhalation (T_{max}), we might have missed this peak concentration with our first blood sample
235 drawn after 30 minutes. This is supported by the only other available pharmacokinetic data from a
236 phase I clinical trial with aerosolized HCQ that came available after our study protocol was
237 developed. Fifteen healthy volunteers inhaled single doses of 5, 10 or 20 mg HCQ. Reported HCQ
238 serum concentrations were mean C_{max} between 22 and 69 µg/L with an early T_{max} within 2-3 minutes.
239 The reported systemic exposure was very low (7-54 µg*h/L), suggesting elimination within 30
240 minutes [33].

241 Local lung concentrations are expected to be higher after inhalation of HCQ compared to oral
242 administration, even though the highest dose of inhaled HCQ in this study (20 mg) is only a fraction
243 of the usual oral HCQ dose (200-800 mg). For example, if the delivered dose of 14.86 mg
244 homogeneously distributes over the lung tissue (843 mL) [47], then a lung tissue HCQ concentration
245 of approximately 40 µM would be achieved. Preliminary results from our own experiments in

246 primary human epithelial cells indicate that HCQ concentrations of approximately 20 to 40 μM do
247 result in a significant reduction in viral load after SARS-CoV-2 infection (manuscript in preparation).
248 This is in contrast to the lack of antiviral effect found by Mulay et al. at an HCQ concentration of only
249 10 μM , which because of the fourfold lower concentration than potentially achievable after HCQ
250 inhalation seems to hold less relevance [48]. Based on these considerations, effective concentrations
251 can potentially be achieved in lung tissue after inhalation of 20 mg HCQ. These high HCQ
252 concentrations and the superior potential of inhaled over oral HCQ should be the new starting point
253 of any further clinical studies on the activity of HCQ against SARS-CoV-2.

254 The concerns about cardiotoxicity of oral HCQ, a well-known drug and generally considered to be
255 safe and well tolerated, were magnified by a large retrospective observational study that reported a
256 strong association between the use of HCQ and ventricular tachycardia and death in hospitalized
257 COVID-19 patients [50]. However, this paper was retracted soon after publication because of
258 concerns about the data validity [49, 50]. White *et al.* state that a lot of confusion has arisen by
259 extrapolating long-term risks of myocardial damage with chronic dosing to short-term exposures,
260 thereby overestimating the risk of ventricular arrhythmias [31]. Our study shows that systemic
261 exposure after inhalation is very low, which is a positive result regarding the risk of systemic toxicity.
262 Also, the concerns for any other possible systemic adverse event should be tempered because of
263 these results.

264 A limitation of our study is that only serum concentrations are measured and not local pulmonary
265 concentrations. So far, only in vitro experiments on Vero cells have shown efficacy and data from
266 human pulmonary concentrations and thus local efficacy are lacking [8, 9]. Since in our study no
267 systemic exposure of HCQ was detected for all participants and for all doses, it is not expected that
268 systemic side effects will occur and HCQ might therefore also be used in patients of older age and
269 with comorbidities.

270 In conclusion, HCQ inhalation using the Cyclops is safe and generally well tolerated by healthy
271 volunteers, except for minor cough and bitter taste. These positive results and the superior safety
272 and efficacy potential of inhaled over oral HCQ strongly encourage the execution of further clinical
273 studies with inhaled HCQ to battle this COVID-19 pandemic.

274

275 **Acknowledgements**

276 We thank Marieke van Rossum and Marina Zenina for their help in the execution of this study.

277

278 **Funding Sources:**

279 The production, labelling and distribution of the HCQ dry powder Cyclops inhalers was provided free
280 of charge by PureIMS.

281 All other funding was supplied by the institutions of the participating authors at University of
282 Groningen and University Medical Center Groningen

283

284 **Conflict of interest:**

285 **YdR:** no conflicts of interest

286 **PH:** The employer of PH has a royalty agreement with AstraZeneca on the sales of the Genuair
287 Inhaler; In addition, PH has a patent WO2015NL50413 20150605 licensed.

288 **MS:** no conflict of interest

289 **FG:** FG is employed by PureIMS, the manufacturer of the Cyclops inhaler.

290 **MB:** no conflicts of interest

291 **IS:** no conflicts of interest

292 **HK:** no conflict of interest

293 **EF:** The employer of HWF has a license agreement with PurelMS on the Cyclops patent

294 (WO2015/187025)

295 **OA:** no conflicts of interest

296 **References**

- 297 1. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. N Engl J
298 Med, 2020. **382**(8): p. 727-733.
- 299 2. WHO, [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4)
300 [sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4).
- 301 3. <https://coronavirus.jhu.edu/map.html>, *COVID-19 Map - Johns Hopkins Coronavirus Resource*
302 *Center*. Accessed October 22th, 2020.
- 303 4. Beigel, J.H., et al., *Remdesivir for the Treatment of Covid-19 - Final Report*. N Engl J Med,
304 2020.
- 305 5. Group, W.H.O.R.E.A.f.C.-T.W., et al., *Association Between Administration of Systemic*
306 *Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis*.
307 JAMA, 2020.
- 308 6. Rynes, R.I., *Hydroxychloroquine treatment of rheumatoid arthritis*. Am J Med, 1988. **85**(4A):
309 p. 18-22.
- 310 7. Schrezenmeier, E. and T. Dorner, *Mechanisms of action of hydroxychloroquine and*
311 *chloroquine: implications for rheumatology*. Nat Rev Rheumatol, 2020. **16**(3): p. 155-166.
- 312 8. Liu, J., et al., *Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in*
313 *inhibiting SARS-CoV-2 infection in vitro*. Cell Discov, 2020. **6**: p. 16.
- 314 9. Yao, X., et al., *In Vitro Antiviral Activity and Projection of Optimized Dosing Design of*
315 *Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2*
316 *(SARS-CoV-2)*. Clin Infect Dis, 2020.
- 317 10. Kuba, K., et al., *A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-*
318 *induced lung injury*. Nat Med, 2005. **11**(8): p. 875-9.
- 319 11. Zhou, D., S.M. Dai, and Q. Tong, *COVID-19: a recommendation to examine the effect of*
320 *hydroxychloroquine in preventing infection and progression*. J Antimicrob Chemother, 2020.
- 321 12. Subbarao, K., et al., *Prior infection and passive transfer of neutralizing antibody prevent*
322 *replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice*. J
323 Virol, 2004. **78**(7): p. 3572-7.
- 324 13. Pahan, P. and K. Pahan, *Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?* J
325 Neuroimmune Pharmacol, 2020. **15**(2): p. 174-180.
- 326 14. Ledford, H., *How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose*
327 *treatments*. Nature, 2020. **580**(7803): p. 311-312.
- 328 15. Stower, H., *Virological assessment of SARS-CoV-2*. Nat Med, 2020. **26**(4): p. 465.
- 329 16. Mingo, R.M., et al., *Ebola virus and severe acute respiratory syndrome coronavirus display*
330 *late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining*
331 *step*. J Virol, 2015. **89**(5): p. 2931-43.
- 332 17. Devaux, C.A., et al., *New insights on the antiviral effects of chloroquine against coronavirus:*
333 *what to expect for COVID-19?* Int J Antimicrob Agents, 2020: p. 105938.
- 334 18. Costedoat-Chalumeau, N., et al., *Hydroxychloroquine: a multifaceted treatment in lupus*.
335 Presse Med, 2014. **43**(6 Pt 2): p. e167-80.
- 336 19. Kuznik, A., et al., *Mechanism of endosomal TLR inhibition by antimalarial drugs and*
337 *imidazoquinolines*. J Immunol, 2011. **186**(8): p. 4794-804.
- 338 20. Gies, V., et al., *Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine*. Front Immunol,
339 2020. **11**: p. 1409.
- 340 21. Gao, J., Z. Tian, and X. Yang, *Breakthrough: Chloroquine phosphate has shown apparent*
341 *efficacy in treatment of COVID-19 associated pneumonia in clinical studies*. Biosci Trends,
342 2020. **14**(1): p. 72-73.
- 343 22. Gautret, P., et al., *Hydroxychloroquine and azithromycin as a treatment of COVID-19: results*
344 *of an open-label non-randomized clinical trial*. Int J Antimicrob Agents, 2020: p. 105949.
- 345 23. Arshad, S., et al., *Treatment with hydroxychloroquine, azithromycin, and combination in*
346 *patients hospitalized with COVID-19*. Int J Infect Dis, 2020. **97**: p. 396-403.

- 347 24. Cortegiani, A., et al., *A systematic review on the efficacy and safety of chloroquine for the*
348 *treatment of COVID-19.* J Crit Care, 2020. **57**: p. 279-283.
- 349 25. Lammers, A.J.J., et al., *Early Hydroxychloroquine but not Chloroquine use reduces ICU*
350 *admission in COVID-19 patients.* Int J Infect Dis, 2020.
- 351 26. Mahévas, M., *No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised*
352 *for COVID-19 infection and requiring oxygen: Results of a study using routinely collected data*
353 *to emulate a target trial.* MedRxiv, 2020.
- 354 27. Geleris, J., et al., *Observational Study of Hydroxychloroquine in Hospitalized Patients with*
355 *Covid-19.* N Engl J Med, 2020.
- 356 28. Tang, W., et al., *Hydroxychloroquine in patients with mainly mild to moderate coronavirus*
357 *disease 2019: open label, randomised controlled trial.* BMJ, 2020. **369**: p. m1849.
- 358 29. Chen, Z., *Efficacy of hydroxychloroquine and azithromycin as a treatment of COVID-19: results*
359 *of a randomized clinical trial.* medRxiv, 2020.
- 360 30. Group, R.C., et al., *Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.* N Engl
361 J Med, 2020.
- 362 31. White, N.J., et al., *COVID-19 prevention and treatment: A critical analysis of chloroquine and*
363 *hydroxychloroquine clinical pharmacology.* PLoS Med, 2020. **17**(9): p. e1003252.
- 364 32. Klimke, A., et al., *Hydroxychloroquine as an aerosol might markedly reduce and even prevent*
365 *severe clinical symptoms after SARS-CoV-2 infection.* Med Hypotheses, 2020. **142**: p. 109783.
- 366 33. Kavanagh, O., et al., *Inhaled hydroxychloroquine to improve efficacy and reduce harm in the*
367 *treatment of COVID-19.* Med Hypotheses, 2020. **143**: p. 110110.
- 368 34. Hoppentocht, M., et al., *The Cyclops for pulmonary delivery of aminoglycosides; a new*
369 *member of the Twincer family.* Eur J Pharm Biopharm, 2015. **90**: p. 8-15.
- 370 35. Dayton, F., *Development of an inhaled hydroxychloroquine sulfate product using the AERx*
371 *system to treat asthma.* Respiratory Drug Delivery 2006.
- 372 36. Wire M, N.N., Corporation A, *Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical*
373 *Program of Novel Treatment for Asthma.* 2006.
- 374 37. Wire M, N.N., Corporation A, *Aradigm Announces the Results of the AERx HCQ Asthma Phase*
375 *2a Study.* 2006.
- 376 38. Garcia-Luzardo Mdel, R., A.J. Aguilar-Fernandez, and G. Cabrera-Roca, *[Idiopathic pulmonary*
377 *haemosiderosis in childhood: a good response to systemic steroids, inhaled*
378 *hydroxychloroquine and budesonide].* Arch Bronconeumol, 2010. **46**(11): p. 612-3.
- 379 39. Graham, B.L., et al., *Standardization of Spirometry 2019 Update. An Official American*
380 *Thoracic Society and European Respiratory Society Technical Statement.* Am J Respir Crit Care
381 Med, 2019. **200**(8): p. e70-e88.
- 382 40. Harris, P.A., et al., *The REDCap consortium: Building an international community of software*
383 *platform partners.* J Biomed Inform, 2019. **95**: p. 103208.
- 384 41. Harris, P.A., et al., *Research electronic data capture (REDCap)--a metadata-driven*
385 *methodology and workflow process for providing translational research informatics support.* J
386 Biomed Inform, 2009. **42**(2): p. 377-81.
- 387 42. Thomson Reuters (Healthcare). *Micromedex® 2.0 11-16-2020*; Available from:
388 <http://www.thomsonhc.com>
- 389 43. Harrison, M.J., et al., *Inhaled versus nebulised tobramycin: a real world comparison in adult*
390 *cystic fibrosis (CF).* J Cyst Fibros, 2014. **13**(6): p. 692-8.
- 391 44. Akkerman-Nijland, A.M., et al., *Colistin dry powder inhalation with the Twincer: An effective*
392 *and more patient friendly alternative to nebulization.* PLoS One, 2020. **15**(9): p. e0239658.
- 393 45. Uttley, L., et al., *Systematic review of the dry powder inhalers colistimethate sodium and*
394 *tobramycin in cystic fibrosis.* Eur Respir Rev, 2013. **22**(130): p. 476-86.
- 395 46. Pauli, E., et al., *Evaluation of an Immediate-Release Formulation of Hydroxychloroquine*
396 *Sulfate With an Interwoven Pediatric Taste-Masking System.* J Pharm Sci, 2020. **109**(4): p.
397 1493-1497.

- 398 47. Armstrong, J.D., et al., *Lung tissue volume estimated by simultaneous radiographic and*
399 *helium dilution methods*. *Thorax*, 1982. **37**(9): p. 676-9.
- 400 48. Mulay, A., et al., *SARS-CoV-2 infection of primary human lung epithelium for COVID-19*
401 *modeling and drug discovery*. bioRxiv, 2020.
- 402 49. Mehra, M.R., et al., *RETRACTED: Hydroxychloroquine or chloroquine with or without a*
403 *macrolide for treatment of COVID-19: a multinational registry analysis*. *Lancet*, 2020.
- 404 50. *James Watson on the behalf of 201 signatories. An open letter to Mehra et al and the Lancet*
405 *(Version 4)*. Available from: <https://zenodo.org/record/3862789#.X5wzpNxYYRA>, 2020.

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

Table 1. In- and exclusion criteria

Inclusion criteria

Healthy volunteer

Age 18-65 years

Obtained written informed consent

Exclusion criteria

Pregnancy or breastfeeding

Contra-indication to (hydroxy)chloroquine or quinine (allergic reaction, prolonged QTc-interval (> 450 msec), long-QT syndrome (LQTS), retinopathy, epilepsy, myasthenia gravis, G6PD-deficiency)

Concurrent use of ciclosporin, digoxin, ritonavir, tamoxifen or tranylcypromine.

Concurrent use of high risk QTc prolongating drugs (amiodarone, erythromycin (daily dose > 1000 mg) or sotalol)

COVID-19 like symptoms, such as fever, cough, or sore throat; only by history taking.

Table 2. Participant characteristics

	<i>N (%) or Mean (range)</i>
<i>Sex (male / female), N (%)</i>	<i>9 (75) / 3 (25)</i>
<i>Age (years)</i>	<i>30 (20 – 53)</i>
<i>FEV1 predicted (%)</i>	<i>101 (90 - 112)</i>
<i>BMI (kg/m²)</i>	<i>26.2 (21.8 – 38.5)</i>
<i>Non-smoking / Ex-smoking /</i>	<i>4 (33) /4 (33)/ 4 (33)</i>
<i>Current smoker, N (%)</i>	

Table 3. Reported adverse events out of 36 HCQ administrations by inhalation

Adverse events	Percentage of total administrations	Percentage of patients
Cough	11.1%	33.3%
Dyspnea	5.6%	16.7%
Bitter taste	100%	100%
Nausea	5.6%	16.7%
Sore throat / respiratory infection	8.3%	25%
Hoarseness	2.8%	8.3%
Spotting	5.6%	8.3%
Dry eyes	2.8%	8.3%

Table 4. change in FEV1 post inhalation compared to baseline in %: mean \pm SD and range

Dose	Change in FEV1 from baseline 35 min post inhalation	P value	Change in FEV1 from baseline 95 min post inhalation	P value
5 mg	-0.98 \pm 1.98	0.123	-1.21 \pm 2.91	0.167
HCQ	(-5.44 – +1.90)		(-7.51 – +2.44)	
10 mg	-0.21 \pm 3.2	0.640	0.21 \pm 2.74	0.097
HCQ	(-7.30 – +3.79)		(-5.31 – +4.66)	
20 mg	-0.98 \pm 1.98	0.123	-1.21 \pm 2.91	0.167
HCQ	(-5.44 – +1.90)		(-7.51 – +2.44)	

Table 5. Change in QTc time in ms

	3,5 h after administration	P value
Before administration	412 ± 21 ms (range 384-441)	
Post 5 mg HCQ	407 ± 19 ms (range 383-439)	0.538
Post 10 mg HCQ	414 ± 15 ms (range 392-447)	0.736
Post 20 mg HCQ	409 ± 12 ms (range 381-423)	0.648